Literature DB >> 14709631

An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes.

Matthew G Soars1, David M Petullo, James A Eckstein, Steve C Kasper, Steven A Wrighton.   

Abstract

Uridine diphosphate glucuronosyltransferases (UGTs) catalyze the glucuronidation of a wide range of xenobiotics and endogenous substrates. However, there is a lack of information concerning the response of human UGTs to inducers, and this observation prompted the current investigation. The glucuronidation of estradiol (3- and 17-positions), naphthol, propofol, and morphine (3- and 6-positions) was assessed against a battery of recombinant human UGTs to determine selective glucuronidation reactions for induction studies. The potential induction of the glucuronidation of estradiol at the 3-position, naphthol, propofol, and morphine at the 3-position was subsequently investigated in cultured primary human hepatocytes against a range of prototypic inducers including dexamethasone, 3-methylcholanthrene (3-MC), phenobarbital, rifampicin, and omeprazole. Treatment with 3-MC induced estradiol-3-glucuronidation (up to 2.5-fold) in four of five donors investigated. Statistically significant increases in naphthol glucuronidation (up to 1.7-fold) were observed following treatment with carbamazepine. UGT1A9-mediated propofol glucuronidation was induced by phenobarbital (up to 2.2-fold) and rifampicin (up to 1.7-fold). However, treatment with alpha-naphthoflavone and tangeretin resulted in a decrease in propofol glucuronidation (30% of control values). Statistically significant induction of morphine-3-glucuronidation was observed in at least three donors following treatment with phenobarbital, rifampicin, and carbamazepine. Each UGT isoform investigated displayed a distinct induction profile. Although statistically significant increases in glucuronidation were observed for each reaction studied, the level of induction was less than that observed for CYP1A2 or CYP3A4 and exhibited a large interdonor variability. The clinical relevance of the induction responses obtained in this study is unclear.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709631     DOI: 10.1124/dmd.32.1.140

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

1.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

Review 4.  Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.

Authors:  M Strolin Benedetti; R Whomsley; E Baltes; F Tonner
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

5.  Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Authors:  Lei Cao; David J Greenblatt; Awewura Kwara
Journal:  Drug Metab Dispos       Date:  2017-06-29       Impact factor: 3.922

6.  Induction of the UDP-Glucuronosyltransferase 1A1 during the Perinatal Period Can Cause Neurodevelopmental Toxicity.

Authors:  Rika Hirashima; Hirofumi Michimae; Hiroaki Takemoto; Aya Sasaki; Yoshinori Kobayashi; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Mol Pharmacol       Date:  2016-07-13       Impact factor: 4.436

7.  Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.

Authors:  Lu Xiong; Chao Gao; Yao-Jie Shi; Xin Tao; Cui-Ting Peng; Juan Rong; Kun-Lin Liu; Qian Lei; Yi-Wen Zhang; Ning-Yu Wang; Luo-Ting Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

8.  Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.

Authors:  Thomayant Prueksaritanont; Karen M Richards; Yue Qiu; Kristine Strong-Basalyga; Alisha Miller; Chunze Li; Roy Eisenhandler; Edward J Carlini
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

9.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.